The substantial beat on both earnings per share and sales estimates for United Therapeutics indicates strong company performance and operational efficiency. This outperformance, especially with a significant year-over-year growth in sales, is likely to instill investor confidence and could lead to a positive short-term impact on UTHR's stock price. The exceedance of analyst expectations by nearly 11% for EPS and over 8% for sales, combined with the impressive year-over-year growth, underscores the company's momentum and may lead to upward revisions of future earnings estimates and stock price targets.